Tag Archives: neuroendocrine tumors

October, 2017

30 October
Novartis to Expand Oncology Business by Acquiring Advanced Accelerator Applications for $3.9 Billion

Basel, October 30, 2017 – Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that …
Share

13 June
Blood Test Predicts Success of Neuroendocrine Cancer Therapy

San Diego, Calif. – Malignant neuroendocrine tumors (NETs) are relatively rare, notoriously difficult to treat, and associated with poor long-term survival. According to research presented at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an investigative blood test could predict how patients will respond …
Share

22 May
Novartis’ Afinitor Meets its Primary Endpoint in a Late-Stage Study in Patients with NET

Novartis’ cancer drug Afinitor extended progression-free survival (PFS) in a late-stage study of patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, paving the way for an expanded indication. The company said that the Phase III RADIANT-4 study Afinitor (everolimus) tablets plus best supportive care in …
Share